メインコンテンツにスキップ

Former Director of Clinical Pharmacology at CDER Joins Certara’s Simcyp Scientific Advisory Board

Dr. Lawrence J. Lesko’s selection underscores biosimulation’s integral role in the drug development process PRINCETON, NJ – Aug. 20, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that Lawrence J. Lesko, PhD, has joined its Simcyp® Scientific Advisory Board (SAB). Dr. Lesko was Director of the Office of Clinical Pharmacology in … Continued

Certara Head of Simcyp Translational Science Appointed to Xenobiotica Editorial Board

PRINCETON, NJ – Aug. 10, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that Iain Gardner, Ph.D., its senior scientific advisor and head of Simcyp translational science, has been appointed to the Xenobiotica Editorial Board. Dr. Gardner will play an active role in the monthly journal’s peer-review process and help to … Continued

Certara Launches Its Simcyp In Vitro Analysis Toolkit to Improve Drug Discovery & Development

This new standalone solution is designed to meet the needs of early-stage drug discovery and development researchers. PRINCETON, NJ – 2015年7月29日 – Certara®, the global biosimulation technology-enabled drug development company, today announced the launch of its Simcyp In Vitro (Data) Analysis (SIVA) Toolkit, version 1.0. The SIVA Toolkit is designed to enable the … Continued

How to Revamp Your Approach to Conventional IVIVC Models

An IVIVC (in vitro-in vivo correlation) is a predictive mathematical model describing the relationship between the in vitro properties of a dosage form and the in vivo responses. Drug developers frequently find IVIVCs useful for a number of reasons: They can use dissolution tests as a surrogate for human bioequivalence (BE) studies. They can support … Continued

25 of 32
Powered by Translations.com GlobalLink OneLink Software